Draft monograph: Thymosin beta-4 — disposition

§3Disposition and amendments

§3.1Disposition table

Table 1. Every submission with its disposition. Each row links to the submission in full.

§3.2Summary by disposition

Table 2. Counts by disposition, with the meaning of each.

§3.3Resulting amendments

1. What happens when the compound is stopped is not addressed — arising from DRAFT-THYMOSIN-BET/002. Discontinuation trajectory is now an assessed outcome in every monograph where a contributing trial measured it, and a recorded evidence gap in every monograph where none did, so that its absence is visible rather than silent.
2. The monograph does not tell a reader that a stated mass may be substantially counter-ion and water — arising from DRAFT-THYMOSIN-BET/013. The monograph now states, at the point where vial contents are first mentioned, that a mass figure is uninterpretable unless it states whether it is peptide content or total solids, and cross-references the content standard in the analytical series.
3. Absence of evidence is presented in a form a reader will take as negative evidence — arising from DRAFT-THYMOSIN-BET/004. A standing formulation has been adopted and is applied wherever an evidence gap is recorded, distinguishing an outcome assessed and not demonstrated from an outcome not assessed. The formulation is identical at every occurrence so that it can be recognised at…
4. A near-isobaric analogue is not distinguished by the identity determination described — arising from DRAFT-THYMOSIN-BET/014. The analytical section now states the resolving power required to discriminate the pair, names the pair explicitly, and records that an identity claim made below that resolution is not conformant with the identity standard.
5. The pharmacokinetic section does not connect half-life to the dosing schedule — arising from DRAFT-THYMOSIN-BET/003. The pharmacokinetic section now states approximate time to steady state alongside the half-life and dosing interval, with the assumption of first-order elimination stated, and records where the assumption is not supported for this compound.
6. The preclinical section is extensive and the clinical section is not — arising from DRAFT-THYMOSIN-BET/011. The preclinical section is reduced in length, placed after the clinical assessment rather than before it, and opens with a standing statement that an effect observed in an animal model is not a clinical outcome and does not support a certainty rating.
7. Evidence for one member of the class is presented as evidence for this compound — arising from DRAFT-THYMOSIN-BET/005. Class-level inferences are now labelled at the point of use, are excluded from the certainty rating for the compound, and are reported in a separate subsection stating which compound the underlying evidence concerns.
8. Effect estimates are given without naming the comparator — arising from DRAFT-THYMOSIN-BET/012. The comparator is now stated in every outcome row, and estimates against different comparators are reported in separate tables with the comparator named in the table caption.
9. The recorded evidence gaps omit outcomes a reader would consider material — arising from DRAFT-THYMOSIN-BET/006. The evidence-gap section is now derived from the anchor and decision-relevant outcomes for the indication, and any such outcome measured by no contributing trial is recorded as not measured rather than omitted.
10. The certainty rating for the principal assessed outcome cannot be traced to the contributing trials — arising from DRAFT-THYMOSIN-BET/015. Each assessed outcome now carries its downgrade domains in the summary-of-findings row, with a short statement of the judgement made in each, so that the rating can be checked domain by domain against the contributing trials.
11. Where the compound is a glucagon-like peptide-1 receptor agonist, the cardiovascular outcome… — arising from DRAFT-THYMOSIN-BET/009. Cardiovascular outcomes are now an assessed outcome with their own certainty rating in every monograph for which a dedicated cardiovascular outcome trial of that compound has reported, and are recorded as not assessed elsewhere.
12. Storage and reconstitution guidance is given without stating what it rests on — arising from DRAFT-THYMOSIN-BET/007. In-use periods now appear only where supported by a cited stability determination on a stated presentation, and elsewhere the monograph records that no in-use stability evidence was identified for this presentation.
13. The monograph should reproduce the approved labelling rather than paraphrase it — arising from DRAFT-THYMOSIN-BET/008. The approved indication and contraindications are now reproduced verbatim from the named authorisation with its version and date, and the posology section reports the labelled schedule and the schedules studied side by side, with the source of each stated.
14. Adverse event frequencies are given without the denominator or the exposure period — arising from DRAFT-THYMOSIN-BET/010. Every reported frequency now carries the number of participants, the number of events and the exposure period, and comparator-arm figures are reported alongside rather than in a separate table.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.